AQASOME nano-encapsulation lets oral peptides like retatrutide and BPC-157 survive the gut. 14 PMIDs cited. The 10 compounds it actually works for.
the 60-second version
- lipinski's rule applies to free peptides, not encapsulated ones. the rule of 5 predicts oral absorption across enterocyte membranes. it does not predict outcomes for nanoparticles taken up by m-cells in peyer's patches. - AQASOMEs are 60-300 nm three-layer nanoparticles with a calcium phosphate core, a trehalose carbohydrate shell, and the peptide adsorbed on the outer surface. - first-pass liver metabolism gets bypassed because nanoparticles route through the intestinal lymphatic system, not the hepatic portal vein. - rybelsus proves the category works. oral semaglutide hits 0.4-2% bioavailability via snac chaperone tech and it's still a multi-billion-dollar drug. - the per-compound pk data for ion's specific formulation is not yet peer-reviewed. the architecture is. the route is. the application is running ahead of the literature.
the hook
retatrutide molecular weight
4,895 Da
lipinski's rule of 5 oral limit
500 Da
rybelsus oral bioavailability
0.4-2%
AQASOME research lineage
34 years
retatrutide is 4,895 daltons. lipinski's rule of 5 says nothing over 500 da gets absorbed orally. so when ion aminos sent a dropper bottle of oral retatrutide, the first reaction was the same one anyone in r/peptides is about to have: this can't possibly work.
then we read the kossovsky 1995 paper. then a stack of 13 others. it's not that the rule is wrong. it's that the rule applies to free peptide bouncing around stomach acid, not peptide adsorbed onto a 200-nanometer ceramic sphere coated in trehalose and routed through your lymphatic system. that's a different shipping container, and the published delivery-technology literature on it goes back 34 years.
this is the writeup for anyone who saw the ion launch and thought "yeah right." every pmid is real. every objection gets answered. if oral nano-peptides work the way the architecture predicts, this is the most interesting thing to happen to peptide therapy since rybelsus. if they don't, you should know exactly why before you spend a dollar.
what are AQASOMEs, in one paragraph
AQASOMEs are self-assembled three-layer nanoparticles, 60 to 300 nanometers across, designed for delivering fragile bioactive molecules like peptides through hostile environments like the gut. nir kossovsky and colleagues described them in the early 1990s. the structure is a calcium phosphate or ceramic core, a polyhydroxy carbohydrate film (usually trehalose or cellobiose) coating that core, and the bioactive payload (the peptide) adsorbed on the outer surface.
the molecular weight problem
retatrutide
4,895 Da
violates lipinski
bpc-157
1,419 Da
violates lipinski
tb-500 fragment
889 Da
violates lipinski
for free, unprotected peptide in a glass of water, lipinski's rule of 5 is right. three things go wrong: stomach acid at ph 1.5 to 3.5 hydrolyzes peptide bonds within minutes; pepsin, trypsin, chymotrypsin, and brush-border enzymes degrade what's left; the fraction that crosses the gut wall hits liver cyp450 enzymes before reaching systemic circulation. the standard oral peptide bioavailability number across the literature is under 1-2%.
rybelsus (oral semaglutide) is the proof that the rule of 5 can be partially defeated. 0.4-2% bioavailability via snac chaperone tech. that turned into a multi-billion-dollar drug.
AQASOMEs go after the same problem from a different angle entirely.
the AQASOME architecture
three layers, built inside out.
layer 1 โ the ceramic core
layer 2 โ the polyhydroxy oligomer film
layer 3 โ the adsorbed peptide
the canonical proof-of-concept is insulin. cherian 2000 demonstrated slower release and prolonged blood-glucose-lowering activity from insulin-AQASOMEs versus standard insulin in rats. the umbrella review by umashankar 2009 PMID: 19931422 and the 2020 protein/peptide AQASOME review PMID: 32337668 summarize the case across insulin, hemoglobin, serratiopeptidase, and antigen delivery.
citation timeline
how AQASOMEs get around stomach acid, proteases, and first-pass metabolism
free peptide bonds hydrolyze at gastric ph. AQASOMEs don't โ the trehalose or cellobiose film vitrifies into a glassy shell that doesn't dissolve until it hits the higher ph of the small intestine.
pepsin in the stomach, trypsin and chymotrypsin in the duodenum, brush-border peptidases downstream โ these enzymes need to physically access the peptide bond to cleave it. an AQASOME puts the peptide on the outer surface of a 60-300 nm sphere, sterically blocked from protease docking by the surrounding carbohydrate matrix.
free peptide absorbed across the gut wall flows into the hepatic portal vein and hits the liver first. nanoparticles in the 60-300 nm range take a different route. they're taken up by m-cells in peyer's patches, the immune sampling cells in gut-associated lymphoid tissue. from there they get packaged into chylomicrons and routed through the intestinal lymphatic system. lymphatic drainage empties into systemic circulation via the thoracic duct. the liver only sees the drug after it's already perfused the rest of the body. first-pass metabolism gets bypassed.
oral insulin in cyanoacrylate nanoparticles vs IV free drug
36% vs 22%
key citations: shakweh 2004 PMID: 16296726 on peyer's patch uptake, managuli 2018 PMID: 30025212 on intestinal lymphatic targeting, the 2017 review (PMC6527526) on the m-cell route.
the open question
how oral retatrutide (ion3r) compares to rybelsus
retatrutide is eli lilly's triple agonist for the GIP, GLP-1, and glucagon receptors. 39 amino acids, 4,895 daltons.
phase 2 obesity (48 wk, 12 mg)
-24.2%
[PMID:37366315]
phase 2 t2d HbA1c reduction
-2.2%
[PMID:37385280]
phase 2a MASH liver fat
-86%
[PMID:38858523]
phase 3 TRIUMPH-4 (68 wk)
-28.7%
lilly press release dec 2025
it is, by every reported metric, the most aggressive weight-loss molecule currently in clinical development. before may 2026, retatrutide existed in exactly two places: lilly's phase 3 trial program and gray-market injectable vials.
ion3r is the first oral formulation.
an AQASOME packages the peptide on a nanoparticle that hides it from acid and proteases, gets taken up by m-cells, routes through the lymphatic system, and skips first-pass entirely. mechanically that's a meaningfully higher ceiling than snac. on published evidence specifically for retatrutide-in-AQASOME, the per-compound bioavailability number has not been peer-reviewed in pk studies as of may 2026. the architecture is published. the route is published. the peptide-in-AQASOME category is published. this specific application is a commercial product running ahead of the formal pk literature.
if your goal is medical management of obesity, injectable retatrutide via a clinical trial is the only formally-evaluated option in 2026. an oral AQASOME drop is a delivery-technology bet on a molecule whose mechanism is established but whose oral pk is not. price it accordingly.
the 10 compounds in the ion lineup
ion didn't ship an arbitrary peptide collection. each compound was selected because the AQASOME carrier solves a specific delivery problem. eleven compounds across five use case categories.
- ipamorelin (712 Da) โ ghrelin agonist, small MW + AQASOME = strong oral candidate, pairs with cjc-1295
- tb-500 (889 Da) โ thymosin beta-4 fragment, recovery + tissue repair, stacks with bpc-157
- cjc-1295 (3,368 Da) โ GHRH analog, zero oral BA before AQASOME, pairs with ipamorelin
- aod9604 (1,815 Da) โ published oral data even without nano-encapsulation PMID: 11146367, lipolytic without IGF-1 stim
- slu-pp-332 (430 Da) โ pan-ERR agonist (NOT a peptide), parent "lacks oral bioavailability" per billon 2025 PMID: 41421047
- ghk-cu (340 Da + copper) โ copper coordination chemistry is fragile, AQASOME protects the metal-peptide bond, skin/hair/ECM PMID: 18644225
- bpc-157 (1,419 Da) โ originally identified in human gastric juice, unusual gastric stability, AQASOME pushes oral BA higher PMID: 29879879
- wolverine stack โ bpc-157 + tb-500, recovery combination
- pt-141 (1,025 Da) โ bremelanotide, mc3r/mc4r agonist, FDA-approved as vyleesi, monitor BP
- ion3r (4,895 Da) โ retatrutide, the headline product, largest payload
- glow stack โ bpc-157 + tb-500 + ghk-cu, aesthetic version of wolverine
why this launch matters
AQASOMEs have lived in academic literature since 1991. ion is the first consumer brand to commercialize the architecture at scale across a full peptide lineup. four things separate this launch from oral peptide gimmicks:
1. lineup breadth. 11 compounds across 5 use case categories on day one.
2. literature-aligned protocol. 30 drops fasted-morning before food matches the published optimum for m-cell uptake.
3. architecture transparency. ion published a clear 3-layer schematic of the carrier in launch materials.
4. stack composition follows the science. wolverine and glow are literature-justified combinations.
answering the objections
myth: oral peptides don't work
myth: molecular weight too big, lipinski says no
myth: first-pass metabolism kills it
myth: dr bachmeier (or any expert) said oral peptides don't work
myth: if it actually worked, big pharma would've done it
myth: show me peer-reviewed pk data for THIS specific product
myth: this is sponsored content / paid promo
dosing and protocol
ion's published protocol:
- 30 drops (1 ml) once daily in the morning, diluted in 1 oz of water, before food
- sensitivity start: 10-15 drops daily, increase by 5 drops every 3-5 days
- fasted morning timing optimizes m-cell uptake (no dietary protein competing for gut-associated lymphoid tissue)
- track from day 1: subjective energy/sleep/recovery, baseline labs, body weight + waist, photos for glow
what NOT to do
what we don't know yet
per-compound oral bioavailability for this specific AQASOME formulation is not in peer-reviewed pk literature as of may 2026. the underlying technology is published. long-term safety data for daily oral AQASOME dosing at scale doesn't exist yet. systemic exposure from an oral drop is almost certainly lower than the equivalent injectable mg dose โ don't assume 1:1. third-party COA verification matters more here than for cheap peptides.
further reading
- /blog/ultimate-shred-stack-retatrutide-tesamorelin-protocol โ injectable retatrutide stack
- /blog/retatrutide-protocol-guide-2026 โ standalone retatrutide protocol
- /blog/bpc-157-vs-tb-500 โ wolverine pair comparison
- /blog/how-to-read-peptide-coa โ verify any oral product's COA
- /compare/retatrutide-vs-tirzepatide โ triple vs dual agonist
- /compound/retatrutide โ live retatrutide prices
- /vendors/scorecard โ peptide vendor trust scorecard
*educational, not medical advice. peptides discussed are research compounds in most jurisdictions and are not FDA-approved for the uses described. retatrutide is investigational and only legally available via clinical trials as of may 2026. talk to a clinician before starting any peptide protocol. ion aminos provided product samples for evaluation. this writeup is not paid promotion.*
the BHG team
Frequently asked
Weekly drops, weekly research
New guides, price-drop alerts, and reader-submitted protocols. One email a week. Unsubscribe anytime.
No spam. Unsubscribe anytime.
Discussion
Sign in to join the discussion
No comments yet โ be the first to share your thoughts!